UBS: Baxalta Is A Buy Even If Shire Buyout Doesn't Happen
According to the report, Shire is in advanced talks to buy Baxalta for about $32 billion in cash and stock excluding debt -- a per share price between $46.50 and $48.
UBS analysts have since reacted to the rumor.
UBS Analyst: We Still Like Baxalta
In a note to subscribers, analyst Matt Miksic explained that it had been his firm's view since its coverage launch in September, "another offer was possible." Miksic's Buy rating on Baxalta is not contingent on a deal, he added.
The analyst also highlighted recent positive performance. "[S]ince declining to engage Shire on its initial offer in August, the company has beat Q3 estimates, raised guidance for 2015, guided to an above-consensus outlook for 2016 and obtained two key new pipeline approvals (Adynovate and Vonvendi.)"
UBS holds a Buy rating on Baxalta. In its initiation last Fall, the firm unveiled a $46 price target on the stock.
At that time, Miksic said its 100-patient UBS Evidence Lab US Haemophilia survey provided the "best feedback we've ever seen" on haemophilia A patients.
Latest Ratings for BXLT
|Aug 2015||William Blair||Initiates Coverage on||Outperform|
© 2017 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.